6/19/2024  5:30:46 PM Chg. -0.900 Volume Bid5:40:00 PM Ask5:40:00 PM Market Capitalization Dividend Y. P/E Ratio
40.800CHF -2.16% 21,667
Turnover: 887,715.275
40.800Bid Size: 9 41.500Ask Size: 50 534.47 mill.CHF - 46.90

Business description

Basilea Pharmaceutica AG, founded in 2000, is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. The company has a portfolio of marketed drugs: Zevtera®/Mabelio® (ceftobiprole) is an intravenous antibiotic from the cephalosporin class amd Cresemba® (isavuconazole) is an intravenous and oral antifungal from the azole class. Furthermore Basilea's pipeline includes three early-stage oncology drug candidates. Basilea Pharmaceutica AG is headquartered in Basel, Switzerland.
 

Management board & Supervisory board

CEO
David Veitch
Management board
Adesh Kaul, Dr. Gerrit Hauck, Dr. Laurenz Kellenberger, Dr. Marc Engelhardt
Supervisory board
Domenico Scala, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Thomas Werner, Ronald Scott, Steven D. Skolsky
 

Company data

Name: Basilea Pharmaceutica AG
Address: Grenzacherstraße 487,CH-4005 Basel
Phone: +41-61-606-1111
Fax: +41-61-606-1112
E-mail: info_basilea@basilea.com
Internet: www.basilea.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 90.35%
IPO date: 3/25/2004

Investor relations

Name: Peer Nils Schröder
IR phone: +41-61-606-1102
IR Fax: +41-61-606-1238
IR e-mail: investor_relations@basilea.com

Company calendar

CW 33 | 8/13/2024 Interim Report 2nd Quarter/6 Months
 

Main Shareholders

Others
 
78.59%
Black Creek Investment Management Inc
 
5.07%
JPMorgan Chase & Co
 
4.98%
CI Investments Inc.
 
4.91%
Credit Suisse Funds AG
 
3.28%
UBS Fund Management
 
3.17%